Prevalence of transmitted HIV-1 drug resistance among female sex workers and men who have sex with men in El Salvador, Central America

Journal of Medical Virology

Volumn 84, Issue 10, 2012, Pages 1514-1521

  Murillo, Wendy ^a,b   Lorenzana de Rivera, Ivette ^a   Albert, Jan ^b   Guardado, María Elena ^c   Nieto, Ana Isabel ^d   Paz Bailey, Gabriela ^c,e  

^a NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Tephinet Inc   (United States)

^d Ministry of Health   (El Salvador)

^e Valle University of Guatemala   (Guatemala)

Author keywords

Drug resistance mutations; El Salvador; Female sex workers; HIV 1; Men who have sex with men; Transmitted drug resistance

Indexed keywords

EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; POL PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CENTRAL AMERICA; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NONHUMAN; PREVALENCE; PROSTITUTION; SAMPLE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; EL SALVADOR; FEMALE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PREVALENCE; SEQUENCE ANALYSIS, DNA; SEX WORKERS; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84865535318     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23381     Document Type: Article

References (43)

1. Ahumada-Ruiz S, Casado C, Toala-Gonzalez I, Flores-Figueroa D, Rodriguez-French A, Lopez-Galindez C. 2008. High divergence within the major HIV type 1 subtype B epidemic in Panama. AIDS Res Hum Retroviruses 24:1461-1466.
2. Baggaley RF, Garnett GP, Ferguson NM. 2006. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3:e124.
3. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CA, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. 2009. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 4:e4724.
4. Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. 2007. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 59:517-524.
5. Cane PA. 2005. Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis 18:537-542.
6. Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D. 2009. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 23:717-724.
7. Daar ES, Richman DD. 2005. Confronting the emergence of drug-resistant HIV type 1: Impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 21:343-357.
8. Dilernia DA, Lourtau L, Gomez AM, Ebenrstejin J, Toibaro JJ, Bautista CT, Marone R, Carobene M, Pampuro S, Gomez-Carrillo M, Losso MH, Salomon H. 2007. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 21:1355-1360.
9. Dobbs T, Kennedy S, Pau CP, McDougal JS, Parekh BS. 2004. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol 42:2623-2628.
10. Ferreira JL, Thomaz M, Rodrigues R, Harrad D, Oliveira CM, Oliveira CA, Batista JP, Ito TS, Brigido LF. 2008. Molecular characterisation of newly identified HIV-1 infections in Curitiba, Brazil: Preponderance of clade C among males with recent infections. Mem Inst Oswaldo Cruz 103:800-808.
11. Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, Mackie NE. 2007. Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS 21:237-239.
12. Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD. 2003. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37:1693-1698.
13. Geretti AM. 2007. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 20:22-32.
14. Jain V, Liegler T, Vittinghoff E, Hartogensis W, Bacchetti P, Poole L, Loeb L, Pilcher CD, Grant RM, Deeks SG, Hecht FM. 2010. Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009. PLoS ONE 5:e15510.
15. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, Wood M, Sandstrom P. 2006. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: Results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42:86-90.
16. Lindstrom A, Albert J. 2003. A simple and sensitive 'in-house' method for determining genotypic drug resistance in HIV-1. J Virol Methods 107:45-51.
17. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD. 2008. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82:5510-5518.
18. Lloyd B, O'Connell RJ, Michael NL, Aviles R, Palou E, Hernandez R, Cooley J, Jagodzinski LL. 2008. Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program. AIDS Res Hum Retroviruses 24:529-535.
19. MOH. 2009a. Ministerio de Salud de El Salvador, Programa Nacional de VIH/SIDA, El Salvador; Centro para la Prevención y el Control de Enfermedades Infecciosas (CDC); United States Agency for International Development (USAID); Universidad del Valle, Guatemala. Encuesta Centroamericana de vigilancia de comportamiento sexual y prevalencia de VIH/ITS en poblaciones vulnerables.
20. MOH. 2009b. Ministerio de Salud de El Salvador, Programa Nacional de ITS/VIH/SIDA. Situación del VIH/SIDA en El Salvador.
21. Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, Karlsson AC, Albert J. 2009. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment. HIV Med 11:95-103.
22. Murillo W, Paz-Bailey G, Morales S, Monterroso E, Paredes M, Dobbs T, Parekh BS, Albert J, Rivera IL. 2010. Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol 49:239-244.
23. Myatt M, Bennett DE. 2008. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 13:37-48.
24. Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José LJC, Franco Estévez R, Donastorg Cabral Y, Batista ALY, Coakley E, Hammer SM, Brudney K. 2012. Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature. AIDS Res Hum Retroviruses 28:667-674.
25. Pandit A, Mackay WG, Steel C, van Loon AM, Schuurman R. 2008. HIV-1 drug resistance genotyping quality assessment: Results of the ENVA7 genotyping proficiency programme. J Clin Virol 43:401-406.
26. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, Green T, Kumar S, Murphy M, Tang A, Taylor S, White D, Underhill G, Pillay D, Cane P. 2004. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 37:1570-1573.
27. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T, Hu DJ, Vanichseni S, Young NL, Choopanya K, Mastro TD, McDougal JS. 2002. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: A simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses 18:295-307.
28. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T, Dobbs T, Constantine N, Overbaugh J, McDougal JS. 2011. Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses 27:265-273.
29. Petroni A, Deluchi G, Pryluka D, Rotryng F, Bortolozzi R, Lopardo G, Bouzas MB, Zapiola I, Garone D, Rodriguez C, Chiocconi E, Lazaro ME, Murano F, Maranzana A, Oliva SM, Aparicio M, Beltran M, Benetucci JA. 2006. Update on primary HIV-1 resistance in Argentina: Emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 42:506-510.
30. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. 2011. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 66:1467-1480.
31. Rodrigues R, Scherer LC, Oliveira CM, Franco HM, Sperhacke RD, Ferreira JL, Castro SM, Stella IM, Brigido LF. 2006. Low prevalence of primary antiretroviral resistance mutations and predominance of HIV-1 clade C at polymerase gene in newly diagnosed individuals from south Brazil. Virus Res 116:201-207.
32. Shafer RW, Schapiro JM. 2008. HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 10:67-84.
33. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215-223.
34. Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J Acquir Immune Defic Syndr 41:439-446.
35. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599.
36. Taylor-Castillo L, Leon-Bratti MP, Solano-Chinchilla A, Herrera-Martinez G, Boza-Cordero R, Leon B, Luftig RB, Visona K. 2010. Variability in HIV-1 partial genomic sequences in Costa Rican patients: Analysis with different bioinformatics tools. Rev Panam Salud Publica 27:23-31.
37. The-SPREAD-Programme. 2008. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22:625-635.
38. UNAIDS. 2009. Global report: UNAIDS report on the global epidemic.
39. UNAIDS. 2010. Global report: UNAIDS report on the global epidemic.
40. Wainberg MA, Moisi D, Oliveira M, Toni TD, Brenner BG. 2011. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother 66:2346-2349.
41. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, Jr., LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE. 2004. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189:2174-2180.
42. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kucherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stockl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. 2005. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 192:958-966.
43. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiebaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chene G. 2011. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 11:363-371.